Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday. Get Spyre Therapeutics alerts:Check Out Our Latest Research Report on Spyre TherapeuticsSpyre Therapeutics Price PerformanceNASDAQ SYRE opened at $16.36 on Friday. Spyre Therapeutics has a 1 year low of $10.91 and a 1 year high of $40.26. Spyre Therapeutics Company Profile(Get Free Report)Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). See AlsoReceive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.